Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2023-02-22 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Cleansing Notice 1 page 139.3KB
Regulatory Filings Classification · 95% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001 regarding the issue of fully paid ordinary shares upon exercise of unlisted share options. It references an Appendix 2A and compliance with disclosure provisions but does not contain financial statements or detailed financial analysis. The document is short (1403 characters) and serves as a regulatory announcement about share issuance and compliance with disclosure laws. This fits the category of a Regulatory Filing (RNS) rather than a full financial report or capital update filing, as it is a formal compliance notice without substantive financial data or capital structure changes beyond the notice itself.
2023-02-22 English
Telix Full Year Results and Investor Conference Call Details 2 pages 151.4KB
Report Publication Announcement Classification · 95% confidence The document is an ASX release announcing the upcoming release of Telix Pharmaceuticals Limited's Full Year Results and Annual Report for the period ended 31 December 2022. It also notifies about an investor conference call/webcast scheduled after the report release. The document itself does not contain the full annual report or detailed financial data but serves as a notification of the report's release and the related investor call. The document length is 4939 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, according to the 'Menu vs Meal' rule, this document should be classified as a Report Publication Announcement (RPA) rather than the Annual Report (10-K) itself.
2023-02-20 English
Investor briefing on ASCO-GU Zircon Phase III Results 2 pages 157.4KB
Investor Presentation Classification · 90% confidence The document is an ASX release announcing an upcoming investor briefing related to the presentation of Phase III clinical trial results at a medical symposium. It includes details about the event, registration information, company background, and legal disclaimers. There are no financial statements, detailed financial analysis, or comprehensive report content. The document is short (6011 characters) and serves as a notification of an investor briefing rather than the briefing or report itself. Therefore, it fits the category of an Investor Presentation announcement or notification. Given the options, the best fit is Investor Presentation (IP) as it is a detailed presentation for investors focusing on clinical trial results and company strategy, even though the actual presentation is upcoming and this is a notification. Confidence is high due to clear event and presentation focus.
2023-02-09 English
Application for quotation of securities - TLX 10 pages 38.7KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX by Telix Pharmaceuticals Limited. It details the issuance and conversion of options into ordinary fully paid shares, including numbers, issue dates, and consideration. The content focuses on securities issuance and capital changes rather than financial results, management changes, or regulatory certifications. It is not a report or announcement of financial performance but a formal notification related to share capital changes and securities quotation. Therefore, the document fits the category of Share Issue/Capital Change (SHA). The document length and detail confirm it is the actual announcement, not just a brief notice or report publication announcement.
2023-02-01 English
Cleansing Notice 1 page 141.7KB
Regulatory Filings Classification · 95% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001 regarding the issue of fully paid ordinary shares upon exercise of unlisted share options. It references an Appendix 2A and details share issuance dates and quantities. The content is a regulatory announcement about share issuance and compliance with disclosure requirements, not a full financial report or detailed capital update. The document length is short (1513 characters) and it serves as a formal notification rather than a report or presentation. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories like Capital/Financing Update or Share Issue/Capital Change, since it is a statutory notice under the Corporations Act rather than a direct capital raising announcement or share issue event notice.
2023-02-01 English
Appendix 4C and Activities Report - December 2022 Quarter 10 pages 246.0KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'APPENDIX 4C QUARTERLY CASH FLOW AND ACTIVITIES REPORT FOR PERIOD ENDED 31 DECEMBER 2022' and contains detailed financial data including cash flow statements, revenue figures, commercial updates, clinical program progress, regulatory updates, and executive leadership changes. It covers a quarterly period ending 31 December 2022 and includes substantive financial data and analysis, not just an announcement or summary. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of detailed financial and operational information for a quarter aligns with the definition of an Interim / Quarterly Report (IR). Therefore, the document should be classified as an Interim / Quarterly Report (IR). Q4 2022
2023-01-17 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.